THE ONE THING
Healthcare conviction is cooling: two names just turned late-stage
By Cathy · Lead Analyst, Fundprints
The week's clearest signal came from inside healthcare, not from the macro noise about oil and Iran. Funds with a proven record in the sector have moved Abivax, a French biotech running late-stage trials for inflammatory diseases, and Pfizer, the global drug giant whose 6%-plus dividend has attracted income investors even as its growth story stays contested, from active building into the Crowded or Fading zone…
The historical echo — what happened the last time this setup appeared — is in the full memo.
THE STORYLINES
Healthcare's two late-stage names: Abivax and Pfizer draw a hold-check
2 names · Healthcare · names in the full memo
ALSO IN THIS EDITION
- What's not happening — the silences and price-vs-evidence divergences nobody else tracks
- The tape — all 8 Prints this week, each with its base rate and why it matters
- For your book — what this week's evidence changes for the names you hold
Read the full memo.
The storylines in full, the historical echo, every Print with its base rate, and what it means for the names you actually own. New edition every week.